Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

The control of invasive Candida infection in very low birth weight infants by reduction in the use of 3rd generation cephalosporin

  • Chang, Yu Jin (Department of Pediatrics, Ajou University School of Medicine) ;
  • Choi, Il Rak (Department of Pediatrics, Ajou University School of Medicine) ;
  • Shin, Won Sub (Department of Pediatrics, Ajou University School of Medicine) ;
  • Lee, Jang Hoon (Department of Pediatrics, Ajou University School of Medicine) ;
  • Kim, Yun Kyung (Department of Pediatrics, Korea University College of Medicine) ;
  • Park, Moon Sung (Department of Pediatrics, Ajou University School of Medicine)
  • Received : 2012.07.24
  • Accepted : 2012.10.24
  • Published : 2013.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the effectiveness of new management policies on the incidence of invasive Candida infections Methods: This observational study involved a retrospective analysis of the patients' medical records. In total, 99 very low birth weight infants, who were admitted to the neonatal intensive care unit at Ajou University Hospital from January 2010 to December 2011, were enrolled for the study. Period I, defined as the period before the revision of management policies, comprised 57 infants; whereas, period II, defined as the period after the implementation of new management policies, comprised 42 infants. The new management policies entailed a reduction in antibiotic and histamine type 2 receptor blocker (H2 blocker) use, duration of central venous catheterization, and duration of endotracheal intubation. Results: There was a significant overall decrease in the use of antibiotics including 3rd generation cephalosporin and H2 blockers (P<0.05), and a significantly lower incidence of invasive Candida infections in period II as compared to period I (0/42 vs. 6/57, respectively; P=0.037). Comparison between infants with invasive Candida infections (n=6) and those without (n=93) showed that gestational age (odds ratio [OR], 0.909; 95% confidence interval [CI], 0.829 to 0.996; P=0.042) and the duration of 3rd generation cephalosporin use (OR, 1.093; 95% CI, 1.009 to 1.183; P=0.029) were statistically significant risk factors. Conclusion: The new management policies effectively decreased overall use of antibiotics, especially 3rd generation cephalosporin, and H2 blockers, which led to a significantly lower incidence of invasive Candida infections.

Keywords

References

  1. Perez-Gonzalez LF, Ruiz-Gonzalez JM, Noyola DE. Nosocomial bacteremia in children: a 15-year experience at a general hospital in Mexico. Infect Control Hosp Epidemiol 2007;28:418-22. https://doi.org/10.1086/513025
  2. Bartels DB, Schwab F, Geffers C, Poets CF, Gastmeier P. Nosocomial infection in small for gestational age newborns with birth weight <1500 g: a multicentre analysis. Arch Dis Child Fetal Neonatal Ed 2007;92:F449-53. https://doi.org/10.1136/adc.2006.114504
  3. Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics 2002;109:34-9. https://doi.org/10.1542/peds.109.1.34
  4. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110(2 Pt 1):285-91. https://doi.org/10.1542/peds.110.2.285
  5. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000;19:319-24. https://doi.org/10.1097/00006454-200004000-00011
  6. Manzoni P, Jacqz-Aigrain E, Rizzollo S, Franco C, Stronati M, Mostert M, et al. Antifungal prophylaxis in neonates. Early Hum Dev 2011;87 Suppl 1:S59-60. https://doi.org/10.1016/j.earlhumdev.2011.01.013
  7. Manzoni P, Farina D, Leonessa M, d'Oulx EA, Galletto P, Mostert M, et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics 2006; 118:2359-64. https://doi.org/10.1542/peds.2006-1311
  8. de Man P, Verhoeven BA, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000;355:973-8. https://doi.org/10.1016/S0140-6736(00)90015-1
  9. Kaiser JR, Cassat JE, Lewno MJ. Should antibiotics be discontinued at 48 hours for negative late-onset sepsis evaluations in the neonatal intensive care unit? J Perinatol 2002;22:445-7. https://doi.org/10.1038/sj.jp.7210764
  10. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics 2000;106:1387-90. https://doi.org/10.1542/peds.106.6.1387
  11. Patel SJ, Oshodi A, Prasad P, Delamora P, Larson E, Zaoutis T, et al. Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance. Pediatr Infect Dis J 2009;28: 1047-51. https://doi.org/10.1097/INF.0b013e3181b12484
  12. Brett S. Science review: the use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care 2005;9:45-50.
  13. Gastmeier P, Geffers C, Schwab F, Fitzner J, Obladen M, Ruden H. Development of a surveillance system for nosocomial infections: the component for neonatal intensive care units in Germany. J Hosp Infect 2004;57:126-31. https://doi.org/10.1016/j.jhin.2003.12.038
  14. Rubin LG, Sanchez PJ, Siegel J, Levine G, Saiman L, Jarvis WR, et al. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices. Pediatrics 2002; 110:e42. https://doi.org/10.1542/peds.110.4.e42
  15. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82:527-32.
  16. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986;33:179-201.
  17. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-34. https://doi.org/10.1016/S0022-3476(78)80282-0
  18. Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed 2006;91:F188-92.
  19. Filioti I, Iosifidis E, Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opin Pharmacother 2008;9:3179-96. https://doi.org/10.1517/14656560802560005
  20. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17. https://doi.org/10.1086/421946
  21. Lopez Sastre JB, Coto Cotallo GD, Fernandez Colomer B; Grupo de Hospitales Castrillo. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003;20:153-63. https://doi.org/10.1055/s-2003-40008
  22. Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr 2005;147:135-41. https://doi.org/10.1016/j.jpeds.2005.04.033
  23. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345:1660-6. https://doi.org/10.1056/NEJMoa010494
  24. Aziz M, Patel AL, Losavio J, Iyengar A, Berven M, Schloemer N, et al. Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants. Pediatr Infect Dis J 2010;29:352-6.
  25. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008;121:703-10. https://doi.org/10.1542/peds.2007-1130
  26. Wade KC, Benjamin DK Jr, Kaufman DA, Ward RM, Smith PB, Jayaraman B, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009;28:717-23. https://doi.org/10.1097/INF.0b013e31819f1f50
  27. Allen U, Richardson S, McGuire W, Bow E, Robinson J, Rotstein C, et al. Pediatric antifungal therapy. Part II: neonatal infections. Minerva Pediatr 2010;62:71-8.
  28. Reed BN, Caudle KE, Rogers PD. Fluconazole prophylaxis in high-risk neonates. Ann Pharmacother 2010;44:178-84. https://doi.org/10.1345/aph.1M364
  29. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr 2011;159:392-7. https://doi.org/10.1016/j.jpeds.2011.02.035
  30. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sanchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009;123: 58-66. https://doi.org/10.1542/peds.2007-3423
  31. Bonnemaison E, Lanotte P, Cantagrel S, Thionois S, Quentin R, Chamboux C, et al. Comparison of fecal flora following administration of two antibiotic protocols for suspected maternofetal infection. Biol Neonate 2003;84:304-10. https://doi.org/10.1159/000073639
  32. Wang Y, Hoenig JD, Malin KJ, Qamar S, Petrof EO, Sun J, et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J 2009; 3:944-54. https://doi.org/10.1038/ismej.2009.37
  33. Claud EC, Walker WA. Hypothesis: inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis. FASEB J 2001;15:1398-403. https://doi.org/10.1096/fj.00-0833hyp
  34. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662-78. https://doi.org/10.1086/313749
  35. Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010;26:1769-78. https://doi.org/10.1185/03007995.2010.487799
  36. Hwang JH, Choi CW, Chang YS, Choe YH, Park WS, Shin SM, et al. The efficacy of clinical strategies to reduce nosocomial sepsis in extremely low birth weight infants. J Korean Med Sci 2005;20: 177-81.

Cited by

  1. Epidemiology of and risk factors for neonatal candidemia at a tertiary care hospital in western China vol.16, pp.None, 2016, https://doi.org/10.1186/s12879-016-2042-9
  2. Antibiotic exposure in neonates and early adverse outcomes: a systematic review and meta-analysis vol.72, pp.7, 2017, https://doi.org/10.1093/jac/dkx088
  3. Persistent candidemia in very low birth weight neonates: risk factors and clinical significance vol.18, pp.None, 2013, https://doi.org/10.1186/s12879-018-3487-9
  4. Reducing Vancomycin Use in a Level IV NICU vol.146, pp.2, 2013, https://doi.org/10.1542/peds.2019-2963